Literature DB >> 27511608

Metabolic syndrome and psoriasis severity in South-East Asian patients: An investigation of potential association using current and chronological assessments.

Leena Chularojanamontri1, Chanisada Wongpraparut1, Narumol Silpa-Archa1, Pichanee Chaweekulrat1.   

Abstract

Although studies regarding prevalence of metabolic syndrome (MS) in Asian psoriatic patients are limited and show varying results, a previous report describes a significant increase in prevalence of MS in Thai psoriatic patients, as compared with rates in the general population. However, no significant association between MS and psoriasis severity using the Psoriasis Area and Severity Index (PASI) was found, which differs from the findings of Korean and Japanese studies. This study aimed at re-evaluating the association between MS and psoriasis severity in Thai patients using current assessment (PASI) and chronological assessment (historical course and interventions). A total of 273 psoriatic patients were recruited. After controlling for age and sex, 96 patients were assigned to the MS group and 96 patients to the non-MS group. Similar to the previous study, no significant differences were identified between metabolic and non-metabolic patients regarding PASI, age of onset, disease duration and family history of psoriasis. However, the numbers of hospitalizations (P = 0.018) and interventions (P = 0.028) were significantly higher in metabolic patients than in non-metabolic patients. Further, a greater number of metabolic components was significantly associated with a higher number of hospitalizations (P = 0.012), pustular or erythrodermic psoriasis episodes (P = 0.049), and interventions (P = 0.005). Body mass index of 23 kg/m2 or more, abdominal obesity and high blood pressure were associated with an increased risk of treatment failure. Using chronological assessment, our study supported that MS negatively affects psoriasis severity and treatment outcomes. Screening for MS is highly recommended for psoriatic patients.
© 2016 Japanese Dermatological Association.

Entities:  

Keywords:  Asian; current and chronological assessments; metabolic syndrome; psoriasis severity; treatment severity

Mesh:

Year:  2016        PMID: 27511608     DOI: 10.1111/1346-8138.13540

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  7 in total

Review 1.  Autoimmunity and autoimmune co-morbidities in psoriasis.

Authors:  Kazuhisa Furue; Takamichi Ito; Gaku Tsuji; Takafumi Kadono; Takeshi Nakahara; Masutaka Furue
Journal:  Immunology       Date:  2018-02-06       Impact factor: 7.397

Review 2.  "Inflammatory skin march" in atopic dermatitis and psoriasis.

Authors:  Masutaka Furue; Takafumi Kadono
Journal:  Inflamm Res       Date:  2017-06-15       Impact factor: 4.575

Review 3.  Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review.

Authors:  Jin Bu; Ruilian Ding; Liangjia Zhou; Xiangming Chen; Erxia Shen
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 4.  Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour.

Authors:  Yuliya Lytvyn; Muskaan Sachdeva; Asfandyar Mufti; Jensen Yeung
Journal:  Drugs Context       Date:  2022-05-31

5.  Datura Metel L. Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis and Inhibits Inflammatory Cytokines Production through TLR7/8-MyD88-NF-κB-NLRP3 Inflammasome Pathway.

Authors:  Bing-You Yang; Yan-Gang Cheng; Yan Liu; Yuan Liu; Jin-Yan Tan; Wei Guan; Shuang Guo; Hai-Xue Kuang
Journal:  Molecules       Date:  2019-06-07       Impact factor: 4.411

6.  Prevalence of metabolic syndrome in Chinese psoriasis patients: A hospital-based cross-sectional study.

Authors:  Xin-Yu Gui; Xiao-Ling Yu; Hong-Zhong Jin; Ya-Gang Zuo; Chao Wu
Journal:  J Diabetes Investig       Date:  2017-05-24       Impact factor: 4.232

7.  Esculetin Ameliorates Psoriasis-Like Skin Disease in Mice by Inducing CD4+Foxp3+ Regulatory T Cells.

Authors:  Yuchao Chen; Qunfang Zhang; Huazhen Liu; Chuanjian Lu; Chun-Ling Liang; Feifei Qiu; Ling Han; Zhenhua Dai
Journal:  Front Immunol       Date:  2018-09-12       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.